140 results about "Arachidonic acid" patented technology

The invention belongs to the technical field of animal molecular markers, and particularly relates to an SNP molecular marker for beef cattle flavor character breeding and application of the SNP molecular marker. The invention proposes that genotype polymorphism of 84181318bp and 84181699bp on chromosome 3 of an international bovine reference genome AR-UCD1.2 version is related to the character of the content of the beef arachidonic acid for the first time, the genotype polymorphism can be used for evaluating the content of the beef arachidonic acid, and beef cattle with specific genotypes at the two sites has relatively high content of the beef arachidonic acid. The site can be used as a molecular marker for evaluating the content of the arachidonic acid in the beef cattle, early prediction and auxiliary screening of beef cattle individuals with excellent meat quality and flavor characters, and a theoretical basis and a technical support are provided for breeding of the beef cattle with high content of the arachidonic acid in the beef cattle.

The invention discloses a KASP molecular marker related to brassica napus quality traits and application of the KASP molecular marker, and belongs to the technical field of molecular genetics. According to the KASP molecular marker related to the brassica napus quality traits, the primers of the KASP molecular marker and the application of the KASP molecular marker and the primers in brassica napus genetic typing or quality traits identification, results show that the KASP molecular marker can accurately identify genotypes, is high in sensitivity and specificity and effectively reduces the error rate. The invention also discloses a brassica napus genotyping / quality identification method, and the result shows that the material with the genotyping result of AA has the characteristics of low erucic acid content, low thioglycoside content, high oleic acid content, high linoleic acid content, low arachidonic acid content and low protein content; gG-type materials exhibit high erucic acid, high thioglycoside, low oleic acid, low linoleic acid, high arachidonic acid and high protein content. Individuals with excellent quality characters can be rapidly screened in early generations, and the long process of character identification after plant maturation in traditional breeding is avoided.

The invention relates to the technical field of cell culture. The invention provides a mesenchymal stem cell culture medium without animal-derived components and application of the mesenchymal stem cell culture medium. The culture medium comprises a basic culture medium and an additive, the additives comprise FGF-2, IGF-1, glutamine, folic acid, serotonin, cholesterol, arachidonic acid, an HEPES buffer solution, sodium bicarbonate, SCF, TGF-beta, PDGF, ascorbic acid and transferrin. The mesenchymal stem cell culture medium disclosed by the invention is completely free of animal-derived components, and meets the requirements of FDA / EMA clinical-grade cell therapy products. The culture medium can support high-density amplification of mesenchymal stem cells, the activity of passage cells is effectively improved, and the amplification time is shortened. The method has remarkable significance in improving the amplification efficiency of the mesenchymal stem cells and promoting and applying factory growth.

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.

An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.

Disclosed herein are compositions and methods for controlling chronic inflammation in a patient. The compositions and methods employ D6-arachidonic acid or an ester thereof (D6-AA) as an anti-inflammatory agent that provides for significant reduction in inflammatory processes. In addition. The compositions of deuterated arachidonic acid or ester thereof comprise, on average, at least about 80% of the hydrogen atoms at each of the bis-allylic sites having been replaced by deuterium atoms and, on average, no more than about 30% of the hydrogen atoms at the mono-allylic sites having been replaced by deuterium atoms.

The invention discloses a positive ion saliva marker related to brain glioma and meningioma and application of the positive ion saliva marker, and relates to the field of biological medicine. The positive ion saliva marker is prepared from one or more of L-arabitol, 20-hydroxyarachidonic acid, sulfonate and palm oil acylethanolamide. The invention provides a kit which is used for detecting positive ion saliva markers related to brain glioma and meningioma and comprises a specific detection reagent. Besides, the invention further provides a computer program product which can judge whether the patient to be detected is a glioma patient or a meningioma patient, so that a solid foundation is laid for subsequent treatment. The method has good feasibility and accuracy, is safe and noninvasive, can effectively distinguish brain glioma and meningioma, and provides a brand new powerful tool for clinical diagnosis.

The invention provides a pulmonary nodule targeting food and medicine homologous composition based on metabonomics screening and application thereof. By analyzing a pulmonary nodule specific metabolic profile, active components, namely platycodin D, mogroside V, oyster active peptide and fermented cordycepin, which can cooperatively regulate and control an arachidonic acid inflammation pathway, a glutathione antioxidant pathway and a tricarboxylic acid cycle energy pathway are reversely screened out. Animal experiments prove that the composition can reduce the volume of pulmonary nodules by 58.3%, human body application shows that the nodules of 76.7% of subjects are reduced, and liver and kidney toxicity is avoided. The composition can be prepared into tablets, capsules and other dosage forms, can be used as functional food or adjuvant therapy drugs for high risk groups of pulmonary nodules, and realizes accurate nutrition intervention.

The invention discloses a compound grease feed additive for improving breeding quality of channa maculata and application. The method comprises the following steps: (1) preparing experimental feed; the method comprises the following steps: respectively preparing an experimental group ARA 1.5 added with 1.5% of arachidonic acid and an experimental group ARA + PC added with 1.5% of arachidonic acid and 1.5% of phosphatidylcholine; (2) feeding; (3) after the culture experiment is finished, treating and detecting the channa maculata; (4) carrying out an artificial propagation test; (5) carrying out ovarian steroid synthesis related gene expression detection; and (6) carrying out data statistical analysis. By adding arachidonic acid (ARA) and phosphatidylcholine (PC) into the feed, the breeding performance of channa maculata and the quality of fry are improved, and the feed has very important significance for improving the aquatic product efficiency of high-quality fry of channa maculata in aquaculture.

The application relates to a probiotic / arachidonic acid composite microcapsule and a preparation method thereof, and belongs to the technical field of microcapsule preparation, and the specific scheme is as follows: a probiotic / arachidonic acid composite microcapsule comprises wall material and core material, the core material is wrapped in the wall material, the wall material comprises sodium alginate and sodium carboxymethyl cellulose, the core material comprises arachidonic acid and probiotics, the arachidonic acid is dissolved in an oily carrier and forms a water-in-oil emulsion with a probiotic bacterial suspension, the sodium carboxymethyl cellulose wraps water-in-oil emulsion droplets, and the sodium alginate reacts with the sodium carboxymethyl cellulose to generate a gel film microcapsule wall material. The method for preparing the probiotic / arachidonic acid composite microcapsule provided by the application is simple to operate, the microfluidic chip is simple to prepare and low in cost, has a high embedding rate, the particle size of the microcapsule is controllable, and the biological activity is good.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The present invention belongs to the technical field of genetic engineering, and particularly relates to an GmHMGS application of a gene and a recombinant overexpression vector in regulating the fatty acid content of plants, and the GmHMGS nucleotide sequence of the gene is shown as SEQ ID NO.1. The present invention uses an overexpression vector of an exogenous gene sequence to introduce the GmHMGS gene shown as SEQ ID NO.1 into plants for overexpression GmHMGS of the gene, and the plants show that the contents of palmitoleic acid, arachidonic acid, docosanoic acid and erucic acid are significantly higher than those of the wild type; at the same time, the contents of stearic acid, oleic acid and linolenic acid are significantly reduced. The present invention regulates the GmHMGS expression of the gene in plants and then uses it to cultivate new plant varieties with adjustable fatty acid content, which provides a new idea for cultivating new crop varieties and has great application value in molecular breeding.

The application discloses application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and belongs to the technical field of feed additives. The application provides application of Fagopyrum cymosum root powder in preparation of products for improving egg quality or intestinal health of laying ducks, and the Fagopyrum cymosum root powder can improve eggshell strength, yolk color and eggshell proportion, improve the content of aspartic acid, threonine, glutamic acid, glycine, cystine and leucine in yolk, improve the content of arachidonic acid and arachidonic acid in yolk, and reduce the content of saturated fatty acid in yolk; the Fagopyrum cymosum root powder can improve the activity of maltase in the mucous membrane of the jejunum of laying ducks, and can improve the diversity and abundance of intestinal flora of laying ducks. The application provides a new strategy for improving egg quality or intestinal health of laying ducks.

The invention discloses a composite elicitor for promoting taxus chinensis embryogenic stem cells to produce paclitaxel and application, and belongs to the technical field of biology. The compound elicitor consists of methyl jasmonate, indolebutyric acid and salicylic acid, and the working concentrations of the methyl jasmonate, the indolebutyric acid and the salicylic acid in a culture medium are respectively as follows: 50-800 mu mol / L of methyl jasmonate, 12.5-50 mu mol / L of indolebutyric acid and 0.1-0.5 mg / L of salicylic acid. Preferably, the jasmonic acid methyl ester is 200 [mu] mol / L, the indolebutyric acid is 25 [mu] mol / L, the salicylic acid is 0.5 mg / L, and 0.1-0.5 mg / L arachidonic acid can be selectively added. The composite elicitor is added in the early stage of the exponential growth phase of the taxus chinensis embryogenic stem cells, and the taxus chinensis embryogenic stem cells are continuously cultured for 5 days, so that the yield of paclitaxel reaches 27.52 mg / L and is 7.86 times that of blank control, and meanwhile, the maximum biomass is obtained. According to the invention, the synergistic interaction of the three elicitors is realized for the first time, the production period is remarkably shortened, a set of efficient and stable paclitaxel production system is established, and an innovative solution is provided for large-scale production of paclitaxel.

The invention discloses a preparation method of an arachidonic acid lipid nano drug delivery system, and relates to the technical field of biology, the lipid nano drug delivery system comprises the following components: (1) ionizable lipid; (2) arachidonic acid; (3) a conjugated lipid that inhibits particle aggregation of a non-cationic lipid or an ionizable lipid; (4) non-cationic lipids or non-ionizable lipids other than (3); (5) metal ions; (6) a nucleic acid drug; the lipid nano drug delivery system is formed by mixing and self-assembling at least the components (1) to (6). According to the novel preparation method of the lipid nano drug delivery system, cancer cells are specifically killed through lipid replacement and simultaneous use of nuclear nucleic acid drugs and metal ions, the treatment accuracy is improved, and the stability and the lysosome escape rate can be increased.

The present invention discloses a breeding method for sturgeon, a sturgeon feed and a preparation method thereof, belonging to the technical field of aquaculture. The sturgeon feed includes basic nutrients such as protein, fat, vitamins and minerals. In the feed, arachidonic acid accounts for 0.1% - 2% of the weight percentage of the feed. In addition, the present invention also provides a preparation method for the above sturgeon feed, including the following steps: S1. Mix fish oil, soybean oil, choline, arachidonic acid, compound multivitamins, compound multiminerals, first flour and water, and granulate to obtain the first granules; S2. Mix the first granules, fish meal, soybean meal, chicken meal, squid visceral powder, sodium carboxymethylcellulose, calcium dihydrogen phosphate and second flour, and granulate and dry to obtain the second granules. In addition, the present invention also provides a breeding method for sturgeon. The feed provided by the present invention can develop the ovaries of 10-year-old Yangtze sturgeon at stage III to stage IV when fed.

The invention provides application of arachidonic acid in delaying reproductive aging, and particularly relates to the technical field of reproductive health. The invention provides application of arachidonic acid in preparation of a product for delaying reproductive aging and / or prolonging the reproductive period. By taking caenorhabditis elegans and mice as examples, the arachidonic acid can obviously activate reproductive aging gonad lysosome, protect oocyte quality and prolong reproductive cycle, thereby delaying reproductive aging. The invention provides a new application prospect of arachidonic acid in the aspects of delaying ovarian aging and protecting fertility.

The invention belongs to the technical field of functional food, and particularly relates to a brain-strengthening and eyesight-improving composition as well as a preparation method, a product and application thereof. The composition is prepared from algal oil, linseed oil, arachidonic acid, marigold extract, zeaxanthin suspension oil, NA nervonic acid and PS phosphatidylserine according to a specific weight part ratio. Wherein the marigold extract is prepared by adopting freeze-grinding pretreatment, combining enzymolysis and an ultrasonic-microwave synergistic extraction technology, and performing nanofiltration membrane concentration and vacuum freeze-drying. According to the composition, through the synergistic effect of all the components and an innovative extraction process, the effects of efficiently strengthening the brain and improving eyesight are achieved, and compared with a traditional formula and an extraction method, the component activity retention and the effective component extraction rate are remarkably improved.

The invention provides a feed additive for improving the hypoxia tolerance function of micropterus salmoides. The feed additive is prepared from the following raw materials in percentage by mass: 20% of arachidonic acid and the balance of maltodextrin. The invention also provides a feed composition of the feed additive. The feed is prepared from the following raw materials in percentage by mass: 450 per mill of fish meal, 50 per mill of fermented hermetia illucens pulp, 69.5 per mill of enzymolysis chicken powder, 60 per mill of chicken liver powder, 60 per mill of enzymolysis soybean meal, 75 per mill of fermented soybean meal, 60 per mill of cottonseed meal, 29 per mill of dextrin, 40.5 per mill of cassava starch, 23 per mill of soybean oil, 23 per mill of linseed oil, 15 per mill of monocalcium phosphate, 5 per mill of choline chloride, 1 per mill of a micropterus salmoides premix, 1 per mill of zeolite powder and 20 per mill of a feed additive. The feed composition is used for improving the hypoxia tolerance of the micropterus salmoides. According to the invention, arachidonic acid is used as a functional active substance to prepare the hypoxia stress resistant functional feed, and the addition of arachidonic acid can significantly activate liver angiogenesis genes, promote the liver angiogenesis level and improve the hypoxia tolerance of largemouth bass.

The invention provides a feed additive for increasing the content of n-3 polyunsaturated fatty acids in pork and a compound feed. The feed additive consists of spartina alterniflora powder and a bacterial enzyme additive, the bacterial enzyme additive is prepared from lactobacillus plantarum, aspergillus niger, yarrowia lipolytica, bacillus subtilis, cellulase, beta-mannase and protease; the compound feed comprises a basic ration and the feed additive. Through development and utilization of spartina alterniflora powder and practice, waste is turned into wealth, a new source of the feed additive is expanded, and the feed additive is added into daily ration, so that the digestibility of neutral detergent fibers of the daily ration is improved, the antioxidant capacity of serum is enhanced, and the contents of alpha-linolenic acid, arachidonic acid and eicosapentaenoic acid in pork are increased.

The invention belongs to the technical field of microorganisms, food science and medicine, and particularly relates to bifidobacterium longum subsp.infantis SZBLI1052 and application thereof. The invention discloses that the obvious synergistic anti-inflammatory effect exists between the specific strain B. longa subsp. Infantis SZBLI1052 and the arachidonic acid (ARA) for the first time, and the specific strain B. longa subsp. Infantis SZBLI1052 has the obvious synergistic anti-inflammatory effect on the arachidonic acid (ARA) and the arachidonic acid (ARA). Compared with the single use of SZBLI1052 or ARA, the combined use of SZBLI1052 and ARA shows a synergistic effect, so that the LPS-induced inflammatory response can be more effectively inhibited, and the protection effect on the intestinal barrier is enhanced. The invention also finds that the strain SZBLI1052 can specifically and obviously consume ARA, and can efficiently metabolize and convert ARA into a key metabolite lipoxin B4 (LXB4) with anti-inflammatory activity. The composition of the SZBLI1052 and the ARA is applied to the infant formula milk, and the synergistic anti-inflammatory effect of the composition is verified. The discovery of the invention lays a solid foundation for developing a new generation of functional infant formula food with synergistic anti-inflammatory characteristics, and has important application potential and industrialization value in the aspect of realizing precise immune nutrition intervention of newborns.

The present invention provides a method for preparing a microbial oil containing dihomo-γ-linolenic acid, the method comprising: adding at least two types of Δ5 desaturase inhibitors to a liquid medium; and culturing a microorganism having reduced or lost Δ5 desaturase activity in the liquid medium to produce the microbial oil containing dihomo-γ-linolenic acid. The content of arachidonic acid in the microbial oil containing dihomo-γ-linolenic acid obtained by the preparation method of the present invention is lower than that in the oil obtained by the conventional method.

This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject.

The application discloses a novel and powerful inhibitor of fatty acid amide hydrolase (FAAH), pyridinone compound (formula I) and therapeutic effect thereof in related diseases, and belongs to the technical field of biological medicine. The inhibitor can inhibit the biological activity of fatty acid amide hydrolase (FAAH), increase the physiological concentration of endogenous arachidonic acid ethanolamine, and play the roles of regulating immunity and resisting inflammation; for example, in inflammatory bowel disease, the inhibitor can significantly improve various pathological and physiological indexes of animals in an inflammatory bowel disease (IBD) model, slow down the progress of the disease, and be effectively used for treating multiple types of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD).

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.

The present invention belongs to the field of food technology, and specifically relates to an infant formula milk powder and a preparation method thereof. The method comprises: uniformly mixing raw cow's milk, lactose, concentrated whey protein powder, edible vegetable oil, galacto-oligosaccharide, vitamin premix, mineral premix, choline chloride and taurine to obtain a mixed liquid; then homogenizing, sterilizing, concentrating and spray drying to obtain milk powder; and finally uniformly mixing with docosahexaenoic acid fish oil powder, arachidonic acid oil and nucleotides to obtain an infant formula milk powder. The present invention proposes a new milk powder formula and preparation method, and on the premise of meeting the requirements of national standards, achieves the purpose of controlling the content of AGEs in the infant formula milk powder by appropriately reducing the content of AGEs precursors such as lactose and adjusting the type and proportion of vegetable oil. In addition, the obtained milk powder has uniform color, uniform thickness, good dispensing, light taste and natural frankincense flavor.

The present invention relates to an immune cell culture medium and a method for culturing immune cells. The immune cell culture medium comprises a cell basal medium and active components added to the cell basal medium, and the active components include: arachidonic acid, β-mercaptoethanol, resveratrol, ginkgo biloba extract, cyclodextrin, alanine-glutamine, and L-ascorbic acid. The cell basal medium comprises RPMI-1640 medium. The cost of the above immune cell culture medium is only 1 / 3 of that of the AIM-V (Gibco) culture system, but the purity, cell survival rate, and killing activity of the CD3AK cells obtained by culturing are higher than those of the AIM-V culture system. That is, the cost of culturing cells with this immune cell culture medium is low, the quality of the obtained cells is good, and the killing activity against cancer cells is strong, and it can be applied to the preparation of immune cells and / or immune cell exosomes.

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.